Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Purpose of review Omega-3 fatty acids (ω-3 FA) are among the most well-recognized health supplements but their cardiovascular benefits have long been controversial owing to inconsistent results from previous cardiovascular outcomes trials (CVOT). In this article, we provide a short review of existing literature followed by recent randomized clinical trial data, with a discussion of the potential clinical implications of these new findings.Recent findings Data from the randomized, controlled trial REDUCE-IT, when viewed within the context of other recently published trials ASCEND and VITAL, add to a growing body of evidence on the use of ω-3 FA therapies in the treatment of atherosclerotic cardiovascular disease (ASCVD). Given the different formulations, dosages, and patient populations studied, CVOTs of ω-3 FA have provided valuable insight into the use of these agents in cardioprotection. Current data suggest that higher dosages of pure eicosapentaenoic acid ω-3 FA formulations provide additional benefit in reduction of ASCVD events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It remains unclear as to why these differences exist and brings to the fore the hypothesis that triglycerideindependent effects of EPA may be in part responsible for the CV benefits seen in the REDUCE-IT trial”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [82]
In the citing paper
“Nutraceutical huperzine A has shown benefits in improving cognitive function, memory function, and daily living activities by reducing oxidative stress [65].”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [65]
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
(1999) · PubMed · Cited by 2,062
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Omega-3 Fatty Acids and Cardiovascular Disease
Mozaffarian, D., & Wu, J. H. Y. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.063 · Cited by 1,771
Omega-3 fatty acids and inflammatory processes: from molecules to man
Calder, P. C. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160474 · Cited by 1,456
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Cited by
Inflammation and cardiovascular disease: are marine phospholipids the answer?
Lordan, R., Redfern, S., Tsoupras, A., & Zabetakis, I. (2020) · Food & Function · doi:10.1039/c9fo01742a · Cited by 101
Diet and lifestyle considerations for patients with prostate cancer
Zuniga, K. B., Chan, J. M., Ryan, C. J., & Kenfield, S. A. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.06.018 · Cited by 78
“Omega-3 fatty acids—Fish oil and flaxseed supplements, rich sources of omega-3 fatty acids, are popular for their perceived benefit in cardiovascular disease[22] and cancer.”
BackgroundWu, Y.-H., Chueh, K., Chuang, S., Long, C., Lu, J., & Juan, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116014 · Cited by 73
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids
Weinberg, R. L., Brook, R. D., Rubenfire, M., & Eagle, K. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.060 · Cited by 63
Miyata, Y., Matsuo, T., Mitsunari, K., Asai, A., Ohba, K., & Sakai, H. (2019) · Antioxidants · doi:10.3390/antiox8050132 · Cited by 62
Metadata
- Authors
- Jia, X., Kohli, P., & Virani, S. S.
- Affiliations
- Baylor College of Medicine (US)
- Michael E. DeBakey VA Medical Center (US)
- Corresponding author
- Virani, Salim S.
- Venue
- Current Atherosclerosis Reports
- Published
- 2019-01
- Volume
- 21
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1523-3804 (ISSN-L)
- 1534-6242
- OpenAlex
- W2909069259
- Cited by
- 39
- References
- 45
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 10 · 2020: 7 · 2019: 10
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Atherosclerosis Reports (publishedVersion)
- PubMed (publishedVersion)
- eCommons - AKU (Aga Khan University) (submittedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Keywords
- omega-3 fatty acids, cardiovascular outcomes, eicosapentaenoic acid, atherosclerotic cardiovascular disease, REDUCE-IT trial, ASCEND trial, VITAL trial, cardioprotection, dosage
- MeSH terms
- Cardiotonic Agents, Cardiovascular Diseases, Diabetes Mellitus, Docosahexaenoic Acids, Heart Failure, Humans, Myocardial Infarction, Eicosapentaenoic Acid, Hypertriglyceridemia, Randomized Controlled Trials as Topic, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials. https://app.cochat.ai/papers/10.1007/s11883-019-0763-0
- The paper
- Jia, X., Kohli, P., & Virani, S. S. (2019). Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-019-0763-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.